GlassScriptPhysician profile
Danika Y Hickman
NPI 1720199110
$622.26
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $188.18 | 2019 | |
| Lilly USA, LLC | $125.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $72.31 | 2019 | |
| Melinta Therapeutics, LLC | $63.34 | 2019 | |
| Genentech USA, INC. | $62.65 | 2019 | |
| Pfizer INC. | $25.38 | 2019 | |
| Aytu Biopharma, INC. | $23.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.14 | 2019 | |
| Merck Sharp & Dohme LLC | $16.70 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danika Hickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.